
Claims

1. A compound represented by formula (III) or a pharmaceutically acceptable salt thereof,



（III）

wherein,

--- is selected from a single bond and a double bond;

T_1 is selected from N, C and CR_6;

T_2 is selected from N, C and CH;

T_3, T_4, T_5 and T_6 are each independently selected from N and CR_7;

X_1 and X_2 are N;

X_3 and X_4 are C;



X_5 and X_7 are each independently selected from CR_8, N, O and S;

X_6 is selected from C and CH;

L_1 is selected from a single bond and -C_{1-3} alkyl-;

R_1 is each independently selected from F, Cl, Br, I, OH, NH_2 and CN;

m is selected from 0, 1, 2, 3, 4 and 5;

R_2 is selected from , and the  is optionally substituted by 1, 2 or 3 R_a;

Y_1 is selected from N, NH and O;

o is 1;

R_3 is -COOH;

R_5 is each independently selected from F, Cl, Br, I and C_{1-3} alkyl;

n is selected from 0, 1 and 2;

or, two adjacent R_5 together form C_{3-5} cycloalkyl;

R_4 is selected from H, F, Cl, Br, I and CH_3;



R_6 is selected from H, F, Cl, Br, I and CH_3;

or, R_4 and R_6 combining with the bonds to which they are attached form a double bond or C_{3-5} cycloalkyl;

R_7 is each independently selected from H, F, Cl and CN;

R_8 is each independently selected from H, F, Cl and CH_3;






R_a is selected from F, Cl, Br and I.



2. The compound as defined in claim 1 or the pharmaceutically acceptable salt thereof, wherein, R_2 is selected from  and , the  and  are optionally substituted by 1, 2 or 3 R_a.


3. The compound as defined in claim 2 or the pharmaceutically acceptable salt thereof, wherein, R_2 is selected from  and .


4. The compound as defined in claim 1 or the pharmaceutically acceptable salt thereof, wherein, L_1 is selected from a single bond and $-CH_2-$.


5. The compound as defined in claim 1 or the pharmaceutically acceptable salt thereof, wherein, m is selected from 0, 1 and 2.



6. The compound as defined in claim 1 or the pharmaceutically acceptable salt thereof, wherein, the structural moiety  is selected from , ,  and .


7. The compound as defined in claim 1 or the pharmaceutically acceptable salt thereof, wherein, the structural moiety  is selected from ,


and


8. The compound as defined in claim 1 or the pharmaceutically acceptable salt thereof, wherein, the structural moiety  is selected from


and


9. The compound as defined in claim 1 or the pharmaceutically acceptable salt thereof, wherein the structural moiety  is selected from ,


and .


10. The compound as defined in any one of claims 1-5 or the pharmaceutically acceptable salt thereof, wherein the compound is selected from,




(I-2)



(I-3)



(P-1)




(P-2) ,

wherein,


 is selected from a single bond and a double bond;

R_1, R_2, R_3, L_1, T_1, T_2, T_3, R_7, m, X_5 and X_7 are as defined in any one of claims 1-5.

11. The compound as defined in claim 10 or the pharmaceutically acceptable salt thereof, wherein the compound is selected from:




(III-1a) and



























(III-1b) ,


wherein, R_1, X_5 and X_7 are as defined in claim 10.


12. A compound represented by the following formula or a pharmaceutically acceptable salt thereof,













.


13. The compound as defined in claim 12 or the pharmaceutically acceptable salt thereof, wherein the compound is selected from:











.

14. Use of the compound as defined in any one of claims 1-13 or the pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of type II diabetes.